Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Triple Combination Therapy With 2 Antivirals and Monoclonal Antibodies for Persistent or Relapsed Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients
Małgorzata Mikulska, Chiara Sepulcri, Chiara Dentone, et al.
Clinical Infectious Diseases (2023) Vol. 77, Iss. 2, pp. 280-286
Open Access | Times Cited: 87

Showing 1-25 of 87 citing articles:

Persistent SARS-CoV-2 infection: significance and implications
Heather Machkovech, Anne M. Hahn, Jacqueline Garonzik‐Wang, et al.
The Lancet Infectious Diseases (2024) Vol. 24, Iss. 7, pp. e453-e462
Open Access | Times Cited: 47
Persistent COVID-19 in immunocompromised patients—Israeli society of infectious diseases consensus statement on diagnosis and management
Suzy Meijer, Yael Paran, Ana Belkin, et al.
Clinical Microbiology and Infection (2024) Vol. 30, Iss. 8, pp. 1012-1017
Closed Access | Times Cited: 10
B-cell-depleted patients with persistent SARS-CoV-2 infection: combination therapy or monotherapy? A real-world experience
Alessandra D’Abramo, Serena Vita, Alessia Beccacece, et al.
Frontiers in Medicine (2024) Vol. 11
Open Access | Times Cited: 9
Efficacy and safety of antiviral plus anti-spike monoclonal antibody combination therapy vs. monotherapy for high-risk immunocompromised patients with mild-to-moderate SARS-CoV2 infection during the Omicron era: A prospective cohort study
Jorge Calderón‐Parra, Andrea Gutiérrez-Villanueva, Gerard Ronda-Roca, et al.
International Journal of Antimicrobial Agents (2024) Vol. 63, Iss. 3, pp. 107095-107095
Open Access | Times Cited: 7
Comparative effectiveness of combination therapy with nirmatrelvir–ritonavir and remdesivir versus monotherapy with remdesivir or nirmatrelvir–ritonavir in patients hospitalised with COVID-19: a target trial emulation study
Ming Hong Choi, Eric Yuk Fai Wan, Ian C. K. Wong, et al.
The Lancet Infectious Diseases (2024) Vol. 24, Iss. 11, pp. 1213-1224
Closed Access | Times Cited: 7
Predicting persistent SARS-CoV-2 shedding in immunocompromised patients: a probability-based approach
Euijin Chang, Jun-Won Kim, Choi‐Young Jang, et al.
Infectious Diseases (2025), pp. 1-10
Closed Access
Efficacy and safety of antiviral therapies for the treatment of persistent COVID-19 in immunocompromised patients since the Omicron surge: a systematic review
Caroline Hirsch, Nina Kreuzberger, Nicole Skoetz, et al.
Journal of Antimicrobial Chemotherapy (2025)
Open Access
SARS-CoV-2 Drug Resistance and Therapeutic Approaches
Sania Batool, Santosh Chokkakula, Ju Hwan Jeong, et al.
Heliyon (2025) Vol. 11, Iss. 2, pp. e41980-e41980
Open Access
Efficacy of antiviral therapy and disease outcomes in COVID-19 patients previously treated with obinutuzumab for follicular lymphoma
Nobuhiro Okagaki, Seishu Hashimoto, Satoshi N. Nakamura, et al.
Tenri Medical Bulletin (2025)
Open Access
Update on Early Combination Therapy with Lastest Monoclonal Antibodies and Antivirals as HIV, HCV, Influenza in Extremely Vulnerable Persons with Sars-Cov-2: A Literature Review and Clinical Experience
Weimer LE
Journal of Clinical Medical Research (2025), pp. 1-28
Closed Access
Early combination therapy of COVID-19 in high-risk patients
Hans Martin Orth, Charlotte Flasshove, Moritz Berger, et al.
Infection (2023) Vol. 52, Iss. 3, pp. 877-889
Open Access | Times Cited: 18
Antiviral combination therapies for persistent COVID-19 in immunocompromised patients
Daniele Focosi, Fabrizio Maggi, Alessandra D’Abramo, et al.
International Journal of Infectious Diseases (2023) Vol. 137, pp. 55-59
Open Access | Times Cited: 16
Optimizing COVID-19 treatment in immunocompromised patients: early combination therapy with remdesivir, nirmatrelvir/ritonavir and sotrovimab
Ivan Gentile, Maria Foggia, Maria Silvitelli, et al.
Virology Journal (2023) Vol. 20, Iss. 1
Open Access | Times Cited: 14
Early initiation of combined therapy in severely immunocompromised patients with COVID-19: a retrospective cohort study
Salvatore Rotundo, Lavinia Berardelli, Sara Palma Gullì, et al.
BMC Infectious Diseases (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 5
Emergence of transmissible SARS-CoV-2 variants with decreased sensitivity to antivirals in immunocompromised patients with persistent infections
Mohammed Nooruzzaman, Katherine Johnson, Ruchi Rani, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 5
Prevention and management of infectious complications in patients with chronic lymphocytic leukemia (CLL) treated with BTK and BCL-2 inhibitors, focus on current guidelines
Małgorzata Mikulska, Chiara Oltolini, Emanuela Zappulo, et al.
Blood Reviews (2024) Vol. 65, pp. 101180-101180
Open Access | Times Cited: 4
Guidance for prevention and management of COVID-19 in children and adolescents: A consensus statement from the Pediatric Infectious Diseases Society Pediatric COVID-19 Therapies Taskforce
Zachary Willis, Carlos R. Oliveira, Mark J. Abzug, et al.
Journal of the Pediatric Infectious Diseases Society (2024) Vol. 13, Iss. 3, pp. 159-185
Open Access | Times Cited: 4
Emerging anti-spike monoclonal antibodies against SARS-CoV-2
Eloy E. Ordaya, Raymund R. Razonable
Expert Opinion on Biological Therapy (2024) Vol. 24, Iss. 3, pp. 191-201
Closed Access | Times Cited: 4
Effectiveness, Tolerability and Prescribing Choice of Antiviral Molecules Molnupiravir, Remdesivir and Nirmatrelvir/r: A Real-World Comparison in the First Ten Months of Use
Cosmo Del Borgo, Silvio Garattini, Carolina Bortignon, et al.
Viruses (2023) Vol. 15, Iss. 4, pp. 1025-1025
Open Access | Times Cited: 13
Synergistic Activity of Remdesivir–Nirmatrelvir Combination on a SARS-CoV-2 In Vitro Model and a Case Report
Anna Gidari, Samuele Sabbatini, Elisabetta Schiaroli, et al.
Viruses (2023) Vol. 15, Iss. 7, pp. 1577-1577
Open Access | Times Cited: 13
Successful management of persistent COVID-19 using combination antiviral therapy (nirmatrelvir/ritonavir and remdesivir) and intravenous immunoglobulin transfusion in an immunocompromised host who had received CD20 depleting therapy for follicular lymphoma
Taketomo Maruki, Hidetoshi Nomoto, Noriko Iwamoto, et al.
Journal of Infection and Chemotherapy (2024) Vol. 30, Iss. 8, pp. 793-795
Closed Access | Times Cited: 3
Suboptimal response to combination therapy with tixagevimab/cilgavimab and remdesivir for persistent SARS-CoV-2 infections in immunocompromised patients
Tzong‐Yow Wu, Pao-Yu Chen, Jann‐Tay Wang, et al.
Journal of Antimicrobial Chemotherapy (2024) Vol. 79, Iss. 5, pp. 1196-1200
Closed Access | Times Cited: 3
Protecting the vulnerable: addressing the COVID-19 care needs of people with compromised immunity
Raymund R. Razonable
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 3
The evaluation of risk factors for prolonged viral shedding during anti-SARS-CoV-2 monoclonal antibodies and long-term administration of antivirals in COVID-19 patients with B-cell lymphoma treated by anti-CD20 antibody
Shuhei Maruyama, Daiki Wada, Shuji Kanayama, et al.
BMC Infectious Diseases (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 3
Combination treatment of persistent COVID-19 in immunocompromised patients with remdesivir, nirmaltrevir/ritonavir and tixegavimab/cilgavimab
Tal Brosh‐Nissimov, Nir Ma'aravi, Daniel Leshin-Carmel, et al.
Journal of Microbiology Immunology and Infection (2023) Vol. 57, Iss. 1, pp. 189-194
Open Access | Times Cited: 10
Page 1 - Next Page

Scroll to top